Key facts
- It has raised $13.0M; the latest was Early Stage VC ($8.9M) in Jul 2025.
- Notable investors include Mana Ventures, Gaingels, Foothill Ventures, Jumpstart Ventures, High Water Venture Partners — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Synfini
- ·The full record, as it builds
Funding rounds
No funding rounds for Synfini are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Synfini
Developer of an artificial intelligence (AI) drug discovery platform designed to accelerate chemistry design, development, and synthesis. The company's platform is powered by integrated neuro-symbolic, robotic automation and extensive chemistry data, and also utilizes streamlined hit discovery with custom target-specific models and advanced models for molecular optimization, enabling scientists to create novel therapeutics.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2023
- Employees
- 5
- Website
- synfini.com/
- Ownership
- Privately Held (backing)
Synfini doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Synfini shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Synfini in its N-PORT filings yet. We sweep new filings monthly.